Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incstar launches hepatitis test line

This article was originally published in Clinica

Executive Summary

Incstar has launched a line of seven hepatitis A and B tests following FDA approval of the final two tests in the microtitre-plate panel. There are 300,000 cases and 5,000 deaths from hepatitis B every year in the US. CDC estimates that there are 1.2 million carriers and the American Liver Foundation says total cost of treating the disease is more than $209 million. Hepatitis A is usually self-limiting. Incstar believes the US market for hepatitis A and B testing is worth $160 million and growing at 5% a year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel